Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCytokinetics Inc

Cytokinetics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
58.53 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
2810649
Market Cap
9635.71M

Momentum Score

…

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
55.74
Low
59.08
High
52 Week Price Range
47.22
Low
88.31
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cytokinetics is a clinical-stage biopharmaceutical company developing small-molecule myosin modulators to treat cardiac and skeletal muscle disorders, including heart failure and neuromuscular diseases. Long-term growth drivers include late-stage clinical progress, potential regulatory approvals and commercial launches, and partnerships or royalty streams that could support revenues.
Key investment risks are clinical and regulatory setbacks, high R&D spending with possible financing needs, and competitive and commercialization execution challenges that may impede market access.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
58.53
Dividend Yield
-
Revenue TTM
67.67M
Revenue Per Share
0.54
Gross Profit TTM
-337.44M
Debt / Equity
-1.95
ROE
-572.15%
Net Debt
402.02M
ROCE
-64.23%
Diluted EPS TTM
-6.90

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -784.96M -589.53M -526.24M -388.95M -215.31M
Net income -784.96M -589.53M -526.24M -402.55M -242.37M
Selling general administrative 284.27M 215.31M 173.61M 177.98M 96.80M
Gross profit 77.91M -320.93M -322.59M -146.22M -89.51M
Reconciled depreciation 10.12M 9.53M 7.21M 5.81M 2.28M
Ebit -784.96M -503.01M -468.58M -324.20M -186.31M
Ebitda -775.27M -493.48M -456.68M -312.86M -185.98M
Depreciation and amortization 9.69M 9.53M 11.89M 11.34M 0.33M
Non operating income net other - - - 11.34M 0.33M
Operating income -612.26M -536.25M -496.20M -324.20M -186.31M
Other operating expenses 700.30M 554.72M 503.74M 418.79M 256.74M
Interest expense 103.87M 86.51M 57.67M 51.16M 29.33M
Tax provision - - - 0.00M 0.00M
Interest income 48.42M 51.53M 25.96M 11.34M 0.33M
Net interest income -55.45M -34.98M -30.91M -39.81M -29.00M
Income tax expense - - 11.72M 13.60M 27.06M
Total revenue 88.04M 18.47M 7.53M 94.59M 70.43M
Total operating expenses 690.17M 215.31M 173.61M 177.98M 96.80M
Cost of revenue 10.12M 339.41M 330.12M 240.81M 159.94M
Total other income expense net -172.70M -53.28M -30.04M -64.75M -29.00M
Net income from continuing ops -784.96M -589.53M -526.73M -332.27M -202.42M
Net income applicable to common shares - - - -388.95M -215.31M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1424.54M 1401.67M 824.32M 1014.77M 841.32M
Other current assets 34.75M 15.28M 11.57M 12.61M 64.03M
Total liab 2084.16M 1537.05M 1210.64M 1122.67M 597.46M
Total stockholder equity -659.62M -135.37M -386.32M -107.90M 243.86M
Deferred long term liab - - - - 87.00M
Other current liab 36.55M 76.44M 53.20M 46.18M 1.54M
Common stock 0.12M 0.12M 0.10M 0.09M 0.08M
Capital stock 0.12M 0.12M 0.10M 0.09M 0.08M
Retained earnings -3486.72M -2701.76M -2112.24M -1585.99M -1207.62M
Other liab - - - 300.54M 270.53M
Other assets - - - 9.69M 7.19M
Cash 882.22M 94.86M 113.40M 65.58M 112.67M
Total current liabilities 202.45M 179.67M 102.68M 84.62M 71.86M
Current deferred revenue - 52.37M - - 34.37M
Net debt 402.02M 693.82M 642.37M 683.76M 157.26M
Short term debt 60.29M 30.50M 27.97M 12.83M 14.86M
Short long term debt 41.18M 11.52M 10.08M - -
Short long term debt total 1284.24M 788.68M 755.77M 749.34M 269.93M
Other stockholder equity 2826.34M 2563.88M 1725.82M 1481.59M 1452.27M
Property plant equipment - - - 80.45M 73.27M
Total current assets 916.98M 1107.94M 628.05M 795.19M 535.67M
Long term investments 335.05M 145.06M 40.53M 46.71M 152.05M
Net tangible assets - - - -107.90M 243.86M
Short term investments 759.70M 981.16M 501.80M 717.00M 358.97M
Net receivables 17.76M 16.65M 1.28M 0.15M 51.82M
Long term debt 1115.98M 645.60M 607.37M 63.81M 47.37M
Inventory - - - -0.15M -51.82M
Accounts payable 105.61M 20.37M 21.51M 25.61M 21.09M
Accumulated other comprehensive income 0.63M 2.40M -0.01M -3.59M -0.87M
Common stock total equity - - - 0.09M 0.08M
Retained earnings total equity - - - -1585.99M -1207.62M
Non currrent assets other 17.34M 7.71M 8.00M 9.69M 7.19M
Non current assets total 507.56M 293.73M 196.26M 219.59M 305.65M
Capital lease obligations 127.08M 131.56M 138.32M 139.72M 127.09M
Long term debt total - - - 63.81M 47.37M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 41.47M -553.10M 349.91M -250.80M -98.91M
Change to liabilities - - - -75.69M 19.76M
Total cashflows from investing activities 16.67M -553.10M - -262.13M -147.78M
Net borrowings 315.95M -9.62M - 473.53M 334.66M
Total cash from financing activities 524.46M 930.61M 221.32M 516.17M 319.98M
Change to operating activities - - - 1.10M 54.80M
Net income -784.96M -589.53M -526.24M -388.95M -215.31M
Change in cash 30.40M -18.17M 47.82M -45.48M 29.68M
Begin period cash flow 95.23M 113.40M 65.58M 112.67M 82.98M
End period cash flow 125.63M 95.23M 113.40M 67.18M 112.67M
Total cash from operating activities -510.01M -395.89M -414.33M -299.52M -142.52M
Issuance of capital stock 0.00M 706.84M 1.31M 15.14M 312.05M
Depreciation 10.12M 9.53M 11.89M 5.81M 2.28M
Other cashflows from investing activities -5.00M - - - -
Dividends paid - - 18.46M - -
Change to account receivables -1.11M -15.37M -1.14M 56.67M -47.40M
Sale purchase of stock - 53.02M -10.52M 17.54M -4.45M
Other cashflows from financing activities -2.47M 233.38M 232.69M 670.00M 12.38M
Change to netincome - - - 78.60M 33.96M
Capital expenditures 24.81M 3.91M 1.42M 11.34M 48.87M
Change receivables - - - 56.67M -47.40M
Cash flows other operating - - - 24.05M 64.19M
Cash and cash equivalents changes - - - -45.48M 29.68M
Change in working capital -35.63M 35.66M 3.09M -24.70M 8.46M
Stock based compensation 112.29M 97.84M 72.06M 47.85M 26.83M
Other non cash items 300.45M 50.60M 20.25M 60.48M 32.38M
Free cash flow -534.82M -399.80M -415.75M -310.85M -191.39M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CYTK
Cytokinetics Inc		 -
-%		 58.53 - 117.65 142.39 60.31 150.50 -15.82
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Cytokinetics Inc

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

650 624 3000

https://www.cytokinetics.com

673

Name Title Year Born
Mr. Robert I. Blum CEO, Pres & Director 1964
Mr. Ching W. Jaw Sr. VP & CFO 1963
Dr. Fady Ibraham Malik FACC, M.D., Ph.D. Exec. VP of R&D 1964
Mr. Andrew M. Callos Exec. VP & Chief Commercial Officer 1956
Dr. James A. Spudich Ph.D. Co-Founder & Member of Scientific Advisory Board 1942
Mr. Jeff Lotz VP of Sales & Operations NA
Mr. Robert C. Wong VP & Chief Accounting Officer 1968
Ms. Joanna Siegall Associate Director of Corp. Communications & Investor Relations NA
Ms. Kari K. Loeser J.D. VP & Chief Compliance Officer NA
Mr. Scott R. Jordan Sr. VP of Global Marketing & Commercial Strategy NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…